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Aim: To investigate the relationship of sodium/iodide symporter (NIS) expression with molecular phenotype of highly and low malig-
nant cell lines of human breast cancer (BC) with different sensitivity to doxorubicin (Dox). Materials and Methods: The cell lines used 
in the analysis included T47D, MCF-7, MDA-MB-231, MDA-MB-468, and MCF/Dox. NIS expression was studied by immuno-
cytochemical method. Results: The strongest iodine symporter expression (248 ± 1.9; 272 ± 3.2 and 289 ± 2.8 points, respectively) 
were found in cells of highly malignant cell lines — MDA-MB-231, MDA-MB-468, and MCF-7/Dox. NIS expression was signifi-
cantly weaker (< 120 points) in two BC cell lines of low malignancy (MCF-7 and T47D). In addition, the reduced sensitivity to Dox 
is associated with elevation of NIS expression in both high and low malignant cells. We have demonstrated correlations between NIS 
levels and certain indices of BC malignancy, namely proliferative activity (r = 0.51), receptor status (estrogen receptor; r = –0.47; 
and progesteron receptor; r = –0.47) and invasiveness (r = 0.46). Conclusions: Our data evidence that NIS expression level correlates 
with BC cells indices of malignancy and their sensitivity to Dox. The results obtained suggest the necessity for further studies of NIS 
expression in BC patients aimed at prognosing disease course and monitoring treatment efficacy with anthracyclines.
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Recent studies in �reast cancer �BC� indicate 
su�stantial varia�ility of morphological variants and 
molecular profile as well as disease course and 
response to treatment [�� �]. High heterogeneity 
and pathogenetic diversity of BC make crucial their 
molecular chara cterization �ased on new �iological 
markers [�]. The special attention should �e paid to the 
studies of the role of iodine meta�olism distur�ances 
in BC occurrence and progression [4]. The pro�lem 
of the possi�le linkage �etween the impairments 
of iodine and the BC occurrence has �een discussed 
repeatedly over many decades� and still remains con-
troversial [5]. �ingle clinical o�servations showed that 
the BC incidence is very low in those regions where 
endemic goiter is rare.
�odium/iodide symporter �NI�� is a glycoprotein 
that is integrated into the �asolateral cell surface; 
it contains �� transmem�rane domains� and is es-
sential component for the thyroid hormones �iosyn-
thesis [�]. It is noteworthy� that NI� is a�le to function 
as iodine transporter only under conditions of its mem-
�rane localization. When the protein translocates from 
mem�rane to cytoplasm� which is typical for certain 
pathological conditions� it loses its functional activity 
and does not provide iodine a�sorption �y cells from 
microvasculature [�]. It is known that functional NI� 
activity depends on various factors: thyroid stimulat-
ing hormones� sex hormones� cytokines� transcrip-
tional and growth factors etc. The majority of research 
is devoted to the NI� activity studies in differentiated 
thyroid carcinoma. Recently� NI� was detected in the 
cells of hormone-dependent tumors� including pros-
tate and BC. According to the literature data the NI� 
expression is o�served in more than 5�% of malignant 
�reast tumors [�]. There are some papers on cor-
relation �etween NI� transcriptional activity� tumor 
receptor status and expression of epidermal growth 
factor receptor with tyrosine kinase activity. However� 
the specific evidence of this relationship is a�sent� and 
the NI� expression in BC cells with varying sensitivity 
to anthracycline cytotoxic drugs remains unclear.
The aim — to investigate the relationship of NI� 
expression with molecular phenotype features of hu-
man BC cells and to clarify participation of this protein 
in the determination of sensitivity to doxoru�icin �Dox�.
MATERIALS AND METHODS
Cell lines and drug treatment. The studies were 
performed in vitro on 5 human BC cell lines: T4�D — 
metastatic �reast ductal carcinoma; MDA-MB-��� and 
MDA-MB-4�� — metastatic �reast adenocarcinoma; 
MCF-� — invasive �reast ductal carcinoma; MCF-�/
Dox — its variant� resistant to Dox.
T4�D cells were cultured in RPMI-��4� medium ��ig-
ma� U�A� supplemented with �ovine insulin ��.� U/ml� 
and ��% fetal �ovine serum �FB��. MCF-� cells were 
grown in DMEM ��igma� U�A� supplemented with 
recom�inant human insulin ��.�� mg/ml� and ��% 
FB�. MDA-MB-��� and MDA-MB-4�� cells were 
cultured in Lei�ovitz’s L-�5 medium ��igma� U�A� 
supplemented with ��% FB�. All cultures were grown 
on glass cover slips in humidified atmosphere with 5% 
CO� at �� °C. The resistant variant MCF-�/Dox were 
originated �y growing parental MCF-� cells with rising 
Dox concentrations �from �.� to �� µg/ml�� respectively. 
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Dox were added twice a week after reseeding. Every 
� months� cell survival rate was analyzed �y MTT as-
say. MCF-�/Dox cells were �� times as much resistant 
to the cytotoxic effect of Dox as parental MCF-� cells. 
The cell lines were o�tained from the Bank of Cell Lines 
from Human and Animal Tissues of the R.E. Kavetsky 
Institute of Experimental Pathology� Oncology and 
Radio�iology �IEPOR� of the National Academy of �ci-
ences of Ukraine.
The high or low malignant phenotype was evaluated 
taking into account receptor status� proliferation activ-
ity and invasive properties [�]. MDA-MB-���� MDA-
MB-4�� and MCF-�/Dox cells were considered highly 
malignant �a�sence of steroid hormone receptors� 
high invasive potential and low adhesive properties�. 
T4�D and MCF-� cells were considered low malignant 
�high expression of estrogen and progesterone recep-
tors� low invasive activity�.
The sensitivity to Dox of explored cell lines was 
measured �y IC�� and IC5�. For assessment of NI� ex-
pression changes caused �y Dox in studied cell lines� 
the cells were incu�ated with the cytostatic at doses 
that corresponded to IC��.
Immunocytochemical assay. The cells were 
fixed on cover slips �in triplicate for each sample� 
in ice-cold methanol:acetone ��:�� at −�� °C for 
��� min and incu�ated with �% �ovine serum al�umin 
solution for �� min. For immunocytochemical assay 
primary аnti-NI� monoclonal anti�ody �Clone FP5A� 
��:�5�� �Thermo �cientific� U�A� was used. UltraVision 
LP Detection �ystem �La� Vision� Thermo �cientific� 
U�A� and DAB Quanto �Thermo �cientific� were used 
according to the instructions of the manufacturers. 
When immunocytochemical reaction was completed� 
the cells were stained with haematoxylin �y Mayer 
and placed in Faramount Aqueous Mounting Medium 
�DakoCytomation� Denmark�. Results were analyzed 
�y light microscopy �× ����� oil immersion� with the 
use of classical H-�core method:
S = 1 • N1+ + 2 • N2+ + 3 • N3+,
where � — «H-�core» index� N�+� N�+ and N�+ — 
num�er of cells with low� medium or high marker ex-
pression [��]. The level of studied markers expression 
was assigned as follows: low — from � to ��� H-score 
points� medium — from ��� to ��� H-score points� and 
high — from ��� to ��� H-score points.
Statistical analysis. �TATI�TIСA �.� computer 
program ��tat�oft Inc.� U�A� was used for statisti-
cal processing of the o�tained results. Differences 
�etween the average values were compared with use 
of �tudent’s t-test; correlation analysis was performed 
using Pearson correlation coefficient. Differences were 
considered as significant with the pro�a�ility not less 
than �5% �р < �.�5�.
RESULTS AND DISCUSSION
As seen from the data presented in Ta�le �� two 
of three highly malignant cell lines used in the study� 
namely MDA-MB-4�� and MCF-�/Dox high were 
Dox resistant. Two low malignant cell lines �T4�D 
and MCF-�� and one highly malignant cell line 
�MDA-MB-���� were sensitive to Dox.
Table 1. The level of sensitivity of BC cells to Dox
Cell lines and their  
malignancy
Inhibitory concentration of Dox
IC30 IC50
T47D low (n = 3) 0.9 1.5
MCF-7 low (n = 3) 1.5 2.5
MDA-MB-231 high (n = 3) 1.8 3.0
MDA-MB-468 high (n = 3) 6.0 10.0
MCF-7/Dox high (n = 3) 15.0 25.0
Immunocytochemical analysis revealed different 
NI� expression in studied cells lines. The highest values 
of iodine symporter expression ��4� ± �.�; ��� ± �.� and 
��� ± �.� points� respectively� were found in highly malig-
nant cell lines MDA-MB-���� MDA-MB-4�� and MCF-�/
Dox �Ta�le ��. NI� expression was significantly weaker 
�<��� points� in two low malignant cell lines �MCF-� and 
T4�D�. In Dox-resistant variant of MCF-� cells �MCF-�/
Dox�� NI� expression was �.5 times as much as in pa-
rental MCF-� cell line �see Ta�le ��.
Table 2. NIS expression in BC cells of different malignancy and sensitivity 
to Dox
Cell line Malignancy features
Sensitivity 
to Dox
NIS expression level 
(H-score, points)
T47D Low High 73.0 ± 2.0
MCF-7 Low High 115.0 ± 1.9
MDA-MB-231 High High 248.0 ± 2.6*
MDA-MB-468 High Middle 272.0 ± 2.5*
MCF-7/Dox High Low 289.0 ± 2.8*,#
Note: *p < 0.05 in comparison with low malignant cells; #p < 0.05 in com-
parison with cells of parental MCF-7 line.
�ince we know that NI� is a�le to transport iodine 
only when it is expressed on cells mem�ranes [��� ��]� 
we attempted to analyze NI� localization in studied 
cells lines. In low malignant cell �T4�D and MCF-��� 
NI� expressed �oth on mem�rane and in cytoplasm� 
�ut in highly malignant cell lines� the cytoplasmic 
reaction with anti�odies against this protein prevailed 
�Fig. ��. It should �e noted that in MCF-�/Dox cells NI� 
relocalized to cytoplasm as compared to the parental 
MCF-� cell line �see Fig. ��. Therefore� in highly ma-
lignant cell lines� Dox resistance is accompanied with 
NI� relocalization.
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Fig. 1. �u�cellular distri�ution of NI� in BC cells of different 
malignancy and sensitivity to Dox
The analysis of correlations allowed us to de-
termine the relations of NI� expression with some 
indices of BC malignancy. Increase in NI� expression 
was associated with the lack of steroid hormones 
receptors in highly malignant cells and in cells with 
phenotype of chemoresistance to Dox �Ta�le ��. The 
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direct correlation �etween NI� expression and indices 
of proliferative activity in cells of low malignancy was 
o�served �see Ta�le ��. We proved the association 
of NI� level with invasive properties of low malignant 
cells and MCF-�/Dox cells �see Ta�le ��. The a�ove 
data confirm the NI� participation in the formation 
of BC cells molecular phenotype.
Table 3. Correlation between NIS expression and indices of malignancy 
of BC cells
Indices Correlation coefficientsLow malignancy High malignancy Resistance to Dox
NIS/estrogen receptors −0.47* −0.49* −0.61*
NIS/progesteron  
receptors −0.43* −0.49* −0.58*
NIS/Ki-67 0.51* 0.25 0.22
NIS/invasiveness 0.46* 0.19 0.54*
Note: *p < 0.05.
In cell cultures supplementation with Dox� marked 
reduction in NI� expression was o�served in T4�D 
and MCF-� cell lines ��y �� and 4�%� respectively�� 
that are characterized �y high sensitivity to this cy-
tostatic drug and in MDA-MB-��� line ��y ��.�%� 
�Fig. ��. �upplementation with Dox did not affect NI� 
level in Dox-resistant MDA-MB 4�� and MCF-�/Dox 
cell lines. These data strongly suggest the role of NI� 
in realization of cytostatics effects of Dox.
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Fig. 2. NI� expression shifts in human BC cells caused �y Dox
We found the correlations �etween NI� expres-
sion and malignant phenotype as well Dox resistance 
in human BC cell lines. The highest NI� expression 
was demonstrated in high malignant cell lines resis-
tant to Dox. Our results coincide with pu�lished data 
on correlations �etween NI� levels and certain indices 
of BC malignancy� namely proliferative activity� recep-
tor status and invasiveness [����5]. The data o�tained 
indicate that elevated NI� level and its su�cellular 
relocalization are associated with the lack expres-
sion of steroid hormone receptors� high proliferative 
activity and invasiveness of BC cells. These features 
may �e associated with the reduced iodine a�sorption 
�y highly malignant cells as the consequence of altered 
NI� functional activity [��]. The detected relationship 
�etween NI� level and sensitivity of human BC cells 
to Dox allows one to suggest NI� participation in the 
mechanisms of realization of Dox cytostatic effects. 
The significant shifts of NI� expression that we found 
in cells with Dox-resistant phenotype are pro�a�ly due 
to the MDR1 gene activation [��� ��].
To sum up� our data demonstrate that NI� expres-
sion level correlates with BC cells indices of malig-
nancy as well Dox resistance in human BC cell lines. 
Further studies of NI� expression in BC patients seem 
to �e advantageous for predicting the disease course 
and monitoring treatment efficacy with antracyclines.
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